HDB Financial Services ₹12,500 Crore IPO to Open on June 25, 2025
HDB Financial Services (HDBFS), the non-banking finance arm of HDFC Bank, is set to launch its highly anticipated ₹12,500 crore initial public offering (IPO). The subscription window will open on Wednesday, June 25, and close on Friday, June 27.
About the IPO
- Issue Structure: The proposed issue is a mix of a fresh issue of ₹2,500 crore and an offer for sale (OFS) of ₹10,000 crore worth of shares from HDFC Bank.
- Price Band: Yet to be announced!
- Subscription Period: The IPO will remain open for three trading days, from June 25, 2025, until June 27, 2025.
- Allotment & Listing: The basis of allotment will be finalised by June 30, 2025, and tentative listing on BSE and NSE is July 2, 2025.
- Book-running Lead Managers: JM Financial Limited, BNP Paribas, Bofa Securities India Limited, Goldman Sachs (India) Securities Private Limited, HSBC Securities & Capital Markets Pvt Ltd, IIFL Capital Services Limited, Jefferies India Private Limited, Morgan Stanley India Company Pvt Ltd, Motilal Oswal Investment Advisors Limited, Nomura Financial Advisory And Securities (India) Pvt Ltd, Nuvama Wealth Management Limited, UBS Securities India Private Limited are the book-running lead managers for the IPO.
- Registrar: MUFG Intime India Private Limited is the registrar for the issue.
- Use of Proceeds: The company intends to use the IPO proceeds to augment the company’s Tier–I Capital Base, meet future capital requirements and support its expansion initiatives.
Click here to explore other Upcoming IPOs
About the Company
HDB Financial Services is one of India’s leading NBFCs that offers secured and unsecured financing, including personal loans, business/SME loans, etc. The company’s revenue from operations increased by 14.32% to ₹7,890.63 crore for the six-month period ended September 30, 2024, from ₹6,902.47 crore for the corresponding period in 2023.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here